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Chemerin is a chemotactic agent that was recently identified as the ligand of ChemR23, 
a serpentine receptor expressed by activated macrophages and monocyte-derived dendritic 
cells (DCs). This paper shows that blood plasmacytoid and myeloid DCs express functional 
ChemR23. Recombinant chemerin induced the transmigration of plasmacytoid and myeloid 
DCs across an endothelial cell monolayer. In secondary lymphoid organs (lymph nodes and 
tonsils), ChemR23 is expressed by CD123
 
 
 
 plasmacytoid DCs and by CD1a
 
 
 
 DC-SIGN
 
 
 
 DCs in 
the interfollicular T cell area. ChemR23
 
 
 
 DCs were also observed in dermis from normal skin, 
whereas Langerhans cells were negative. Chemerin expression was selectively detected on 
the luminal side of high endothelial venules in secondary lymphoid organs and in dermal 
endothelial vessels of lupus erythematosus skin lesions. Chemerin
 
 
 
 endothelial cells were 
surrounded by ChemR23
 
 
 
 plasmacytoid DCs. Thus, ChemR23 is expressed and functional in 
plasmacytoid DCs, a property shared only by CXCR4 among chemotactic receptors. This 
finding, together with the selective expression of the cognate ligand on the luminal side 
of high endothelial venules and inflamed endothelium, suggests a key role of the ChemR23/
chemerin axis in directing plasmacytoid DC trafficking.
 
DCs are potent antigen-presenting cells with a
unique ability to induce T and B cell responses
as well as immune tolerance (1, 2). Among
human peripheral blood DCs, at least two dis-
tinct subsets have been defined, based on the
expression of CD11c, namely CD11c
 
 
 
 myeloid
DCs (M-DC) and CD11c
 
 
 
 plasmacytoid DCs
(P-DC; reference 1). In addition, a minor, still
poorly characterized population of CD11c
 
 
 
BDCA-3
 
 
 
 DCs has been described previously
(3). M-DC express myeloid markers such as
CD13 and CD33, the stimulatory receptor Ig-
like transcript 1, and can produce high levels of
IL-12 (4). Conversely, P-DC have a morphol-
ogy  resembling plasma cells; are devoid of
myeloid markers; express high levels of CD4,
CD62 ligand, and CD123; and can produce
high levels of IFN-
 
 
 
 (5–7). This dichotomy
observed in human blood is further extended at
the tissue level, where P-DC and many M-DC
subpopulations can be recognized based on their
morphology, location, and phenotypic profile.
M-DC are located in peripheral nonlym-
phoid tissues at an immature functional state
where they exert a sentinel function for incom-
ing antigens. After antigen uptake, in the con-
text of an inflammatory reaction, M-DC leave
peripheral sites and reach secondary lymphoid
organs by lymphatic vessels (5, 6). In contrast,
P-DC are typically absent in peripheral tissues
under homeostatic conditions and are believed
to leave the circulation to enter secondary lym-
phoid organs through the interaction with high
endothelial venules (HEVs; references 5, 6).
However, recently published papers demon-
strated P-DC recruitment also in some inflamed
skin lesions, such as those associated with sys-
temic lupus erythematosus (LE; references 5, 8),
in nasal mucosa during allergic reactions, and in
tumors (for review see reference 5).
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Differences in distribution and tissue recruitment during
inflammatory conditions between M-DC and P-DC may
reflect distinct functional properties and be explained by spe-
cific migratory mechanisms. Blood DC subsets express a
similar pattern of chemotactic receptors, including CCR2,
CCR5, CXCR2, CXCR3, CXCR4, and PAFR (9). How-
ever, circulating P-DC, in contrast with M-DC, fail to mi-
grate in response to inflammatory chemokines, whereas both
subsets respond to lymph node–homing chemokines (i.e.,
CCL19 and CCL21) after maturation (9). Thus, the only
chemotactic factor presently known for immature P-DC in
vitro is CXCL12, the ligand of CXCR4. However, the
mechanisms leading to the in vivo recruitment of P-DC to
normal and inflamed tissues are still poorly understood.
Chemerin is a novel protein identified as the natural
ligand of ChemR23, a previously orphan protein G–coupled
receptor expressed by immature DCs and macrophages (10).
Chemerin was purified from ovarian cancer ascites and found
to correspond to the product of the Tig-2 gene. Chemerin is
expressed by many tissues, including spleen and lymph
nodes, and is secreted as prochemerin, a poorly active pre-
cursor protein. Extracellular proteases convert prochemerin
into a full agonist of ChemR23 by proteolytic removal of the
last six amino acids (10, 11). Previous work has shown that
chemerin induces calcium fluxes, mitogen-activated protein
kinase activation, and chemotaxis of monocyte-derived im-
mature DCs, whereas LPS- or CD40L-mature DCs do not
express functional ChemR23 receptors. The aim of this
work was to investigate the functional expression of ChemR23
in human blood DC subsets. Here, we report that ChemR23
is expressed and functional in M-DC and most importantly
in P-DC, a property shared only by CXCR4. The ChemR23
ligand, chemerin, is selectively expressed in HEVs and in LE
skin lesions, a prototypic inflammatory condition character-
ized by tissue accumulation of P-DC. These data strongly
suggest that the ChemR23/chemerin axis may play a key
role in regulating the trafficking of P-DC.
 
RESULTS AND DISCUSSION
Expression and function of ChemR23 in blood 
MHC class II
 
 
 
 leukocytes
 
In a previous work, we reported that chemerin represents a
new chemotactic factor for monocyte-derived DCs (10).
Experiments were performed with the aim to characterize
the expression of ChemR23 in circulating leukocytes. Fig. 1 a
shows that ChemR23 expression was mainly present in
MHC class II
 
 
 
 cells and in a minor subset of CD3
 
 
 
 and
CD20
 
 
 
 lymphocytes. Within blood mononuclear cells,
MHC class II
 
 
 
 cells were the only cells that migrated in re-
sponse to chemerin (unpublished data). The expression of
ChemR23 was further investigated in MHC-II
 
 
 
 cells. Fig. 1 b
shows that ChemR23 was expressed by the three major
monocyte subsets, namely CD14
 
 
 
CD16
 
 
 
, CD14
 
 
 
CD16
 
 
 
,
and CD14
 
lo
 
CD16
 
 
 
. However, a statistically significant dif-
ference among the three populations was found both in
terms of percentage of positive cells and intensity of mem-
brane staining (mean fluorescence intensity [MFI]), with the
predominant CD14
 
 
 
CD16
 
 
 
 population having the lowest
levels of membrane fluorescence (MFI).
The three major blood DC subsets were investigated on
the basis of the expression of specific membrane markers:
BDCA-1 (M-DC), BDCA-4 (P-DC), and BDCA-3 (3). Fig.
2 a shows that ChemR23 was expressed by 
 
 
 
40% of the cir-
culating M-DC population and by virtually all P-DC. DC
maturation (
 
 
 
85% CD83
 
 
 
 cells), achieved in the presence of
LPS (M-DC) or influenza virus (P-DC), did not significantly
affect the percentage of ChemR23
 
 
 
 cells, and only induced a
decrease of the mean channel fluorescence (Fig. 2 a). On the
contrary, ChemR23 was only modestly expressed (
 
 
 
30% pos-
itive cells) by BDCA3
 
 
 
 DCs, regardless the state of maturation.
Next, we evaluated the ability of chemerin, the ChemR23
ligand, to induce DC transmigration across an endothelial cell
monolayer. Chemerin induced a dose-dependent migration
of immature M-DC and P-DC, with a peak observed at 100
pM. Compared with the migration observed in response to an
optimal concentration of CXCL12 (12 nM), chemerin in-
Figure 1. Expression of ChemR23 in leukocytes. PBMCs were isolated 
as described in Materials and methods and stained for ChemR23 expression. 
(a) PBMC subsets were analyzed by FACS analysis. One experiment repre-
sentative of four independent experiments is shown. (b) PBMCs were ana-
lyzed for the expression of CD14 and CD16 and three populations of mono-
cytes were discriminated: CD14 CD16 , CD14loCD16 , and CD14 CD16 . 
ChemR23 expression was investigated in monocyte subsets. The values 
represent the mean   SD of positive cells or intensity of membrane stain-
ing (MFI; n   4; *, P   0.05; **, P   0.01 by one-way analysis of variance 
with Tukey post test). The flow cytometry histograms are the result of one 
experiment representative of four independent experiments. 
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duced the migration of a similar percentage of M-DC,
whereas P-DC migration was 
 
 
 
50% of that induced by
CXCL12. Therefore, chemerin is characterized by potency
 
 
 
100-fold higher (peak chemotactic concentration) and by a
similar (M-DC) or slightly reduced (P-DC) efficacy (percent-
age of migrated cells) as compared with CXCL12 (Fig. 2 b).
Chemotaxis of both M-DC and P-DC to chemerin was com-
pletely blocked in the presence of an anti-ChemR23 moAb,
proving the involvement of ChemR23 in chemerin-induced
DC migration (unpublished data). Of note, chemerin-induced
migration of M-DC and P-DC was respectively 1.6- and 3.4-
fold more efficient when assessed in transmigration assays than
using bare filters. This result suggests that chemerin presenta-
tion by endothelial cells is required for optimal interaction
with ChemR23
 
 
 
 DCs. It was reported previously that
CXCR3 ligands increase P-DC migration in response to
CXCL12 (12, 13). Therefore, P-DC migration was tested us-
ing chemerin in combination with different concentrations of
CXCL10 or CXCL12 in the lower wells. P-DC migration to
chemerin was never increased by the presence of these two
chemokines, indicating that ChemR23 does not cooperate
with CXCR3 and CXCR4 for cell migration (unpublished
data). Mature M-DC and P-DC did not migrate in response
to chemerin (Fig. 2 b), but normally migrated in response to
CCL19, one of the CCR7 ligands. It is noteworthy that ma-
ture DCs retained high levels of ChemR23 expression,
whereas they were unresponsive to the cognate agonist. Thus,
the maturation process induces the uncoupling of ChemR23
with no major changes in its membrane expression. All in all,
these results show that chemerin represents a new chemotac-
tic factor for immature DCs. Most importantly, ChemR23
represents the only chemotactic receptor, in addition to
CXCR4, that is active in immature P-DC.
Chemerin belongs to the cathelicidin/cystatin family of
proteins, which includes precursors of bactericidal peptides
(cathelicidins), precursors of mediators active on leukocytes
through protein G–coupled receptors (prokininogen, cathe-
licidin precursors), as well as cysteine protease inhibitors
(cystatins). Elevated chemerin production was found in
ovarian cancer ascites and in the synovial fluids of rheuma-
toid arthritis patients (10). Prochemerin transcripts were also
found in the skin of psoriatic subjects (14). In the bone stro-
mal cell line ST2, the chemerin gene was reported to be in-
duced by 1,25-dihydroxy-vitamin D3 (VitD3) and dexa-
methasone (15). Therefore, it is likely that chemerin represents
an important signal involved in the recruitment of DCs dur-
ing inflammation and autoimmune diseases, and at tumor
sites. The up-regulation of chemerin production by antiin-
flammatory signals such as VitD3 and dexamethasone postu-
lates a role for chemerin in all the conditions characterized
by a “type 2/alternative” state of activation, similar to that
present in tumor-associated leukocytes (16).
 
Expression of ChemR23 by P-DC and M-DC in human tissues
 
At the tissue level, many DC subpopulations can be recog-
nized based on their morphology, location, and phenotypic
profiles. For instance, Langerhans cells express CD1a and Lan-
gerin and are exclusively distributed within epithelial surface;
in contrast, the so-called “interstitial DCs,” typically repre-
sented by dermal DCs, are mainly CD1a
 
 
 
 and express DC-
SIGN and the mannose receptor. In lymphoid organs, DC
subsets are recognizable in B and T cell compartments and in-
clude, respectively, germinal center DCs and Langerhans-
derived interdigitating DCs in T cell paracortical area (5, 6).
The interfollicular area separates nodular lymphoid compart-
ments. The latter is highlighted by the HEVs and populated
by many leukocyte populations, including lymphocytes, macro-
phages, plasma cells, and at least two distinct DC subpopula-
tions, namely CD68
 
 
 
DC-SIGN
 
 
 
 DCs (17) and P-DC (5).
Figure 2. Expression of functional ChemR23 in blood DC subsets. 
Blood DC subsets were isolated as described in Materials and methods and 
stained for ChemR23 expression. Maturation of DCs was achieved by incu-
bation with LPS (BDCA-1 ), influenza virus (BDCA-4 ), or LPS and influ-
enza virus (BDCA-3 ) for 24 h. (a) DC subsets were analyzed by FACS analy-
sis. (b) DC subsets were tested for their ability to migrate across an 
endothelial cell monolayer in response to chemerin or to an optimal con-
centration (12 nM) of CXCL12 (immature DCs) or CCL19 (mature DCs). The 
values represent the mean   SD of triplicate data points and are repre-
sentative of at least five different experiments performed with indepen-
dent donors. Note the different scale used in the left versus right panels. 
(iDC) Immature DCs. (mDC) Mature DCs. *, P   0.05 by paired Student’s t test. 
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The expression of ChemR23 was investigated by immu-
nohistochemistry in lymph nodes and tonsils. In lymph
nodes, numerous ChemR23
 
 
 
 cells with a dendritic morphol-
ogy were located in the interfollicular compartment (Fig. 3 a).
These cells were identified by double immunofluorescence as
DC-SIGN
 
 
 
 (Fig. 3 b) and CD1a
 
 
 
 cells (Fig. 3 c), two phe-
notypic markers that identify distinct nodal myeloid DC pop-
ulations (17). On the basis of their phenotype and location,
these cells are believed to represent the nodal counterpart of
peripheral blood DC-SIGN
 
 
 
 DCs (18, 19) that are recruited
into the lymph nodes from the blood through the HEVs, or a
population of dermal DCs migrated to the lymph node.
ChemR23 reactivity was also present on CD123
 
 
 
 and
BDCA-2
 
 
 
 P-DC (Fig. 3 d and its inset), either scattered as
single cells or in clusters close to HEVs. ChemR23 expres-
sion was not restricted to the interfollicular compartment and
was also observed in sinus macrophages and in scattered cells
within the germinal center (Fig. 3, a and d). This latter popu-
lation coexpressed CD68
 
 
 
 and represents germinal center
macrophages (unpublished data). No reactivity was observed
on B and T lymphocytes. These results indicate that
ChemR23 expression is retained by P-DC and M-DC after
their recruitment to secondary lymphoid tissues.
The expression of ChemR23 was also investigated in
normal skin. A strong reactivity for ChemR23 was identified
in cells located in the upper and intermediate dermis (Fig. 3 e).
These ChemR23
 
 
 
 cells displayed fusate/dendritic morphol-
ogy and coexpressed DC-SIGN (Fig. 3 f) as well as the man-
nose receptor (Fig. 3 f, inset), thus corresponding to dermal
DCs (19). On the contrary, ChemR23 expression was never
detected in the cutaneous Langerhans cells (Fig. 3, e and f)
and in the Langerhans cell–derived paracortical interdigitat-
ing dendritic cells that accumulate in the lymph node during
dermatopatic lymphadenitis (reference 20 and not depicted).
These observations clearly indicate that chemerin is unlikely
to be a relevant chemotactic factor for the homing of
Langerhans cell precursors to the skin, as well as for the mi-
gration of Langerhans cells to superficial lymph nodes.
 
Expression of chemerin by HEVs in secondary 
lymphoid organs
 
Due to the abundance in ChemR23
 
 
 
 cells in secondary
lymphoid organs (lymph nodes and tonsils) and normal skin,
the distribution of chemerin was also investigated in these
tissues. Chemerin reactivity was primarily expressed in the
interfollicular area of lymph nodes and tonsils (Fig. 4 a), the
site where the majority of ChemR23
 
 
 
 cells also localize.
The strongest reactivity was observed in endothelial cells
with cuboidal/cylindrical morphology corresponding to HEVs.
The identity of these chemerin
 
 
 
 cells was further confirmed
on the basis of the coexpression of Factor VIII, a specific en-
dothelial cell marker (Fig. 4 b, inset), as well as CD123 (Fig.
4 a, inset) and CLA/Heca452 (Fig. 4 b), two markers also
expressed by tissue P-DC (5). Of note, in HEVs, the highest
expression of chemerin was observed at the luminal side
(Fig. 4 b). The presence of P-DC positive for ChemR23
in close proximity of HEVs that express chemerin suggests
that chemerin represents an alternative/additional signal to
CXCL12 for the recruitment of blood P-DC into lymph
nodes across HEVs (21). In this respect, it is intriguing that
the pattern of chemerin immunoreactivity resembles that
observed with an anti-CXCL12 antibody (reference 12 and
unpublished data). In addition to HEVs, chemerin expres-
sion was also found on sparse spindle cells located in the
perivenular area (Fig. 4 a). Based on their morphology, this
population is likely to represent stromal cells; their precise
identity is currently under investigation.
HEVs were shown to produce CCL21, which accumu-
lates at their luminal side. Other chemokines were detected on
the surface of HEVs, although they were produced by non-
Figure 3. ChemR23 expression in secondary lymphoid organs and 
normal skin. In secondary lymphoid organs, ChemR23 reactivity is ob-
served in the interfollicular (IF) area and in tingible body macrophages of 
the germinal center (GC) (a and d). In the interfollicular areas, ChemR23  
cells present a sparse perivenular distribution (a, black arrowheads), a DC 
morphology, and coexpress DC-SIGN (b, white arrowheads) and CD1a  
(c, white arrowheads). CD123 ChemR23  plasmacytoid DCs (P-DC; yellow 
cells) are also observed in the interfollicular area (IF) in proximity to a 
CD123  HEV (d), as cluster (d, white asterisk) or as sparse cells coexpressing 
the P-DC–specific marker BDCA-2 (d, inset). In normal skin, ChemR23 
reactivity is observed in dermal cells with fusate/dendritic morphology (e) 
coexpressing DC-SIGN (f, white arrowheads) and mannose receptor (f, inset). 
Indirect immunoperoxidase technique was applied (a and e); nuclei were 
counterstained with hematoxylin. Double immunofluorescence was per-
formed (b–d and f), using Texas red–conjugated secondary antibodies for 
anti-ChemR23 (b–d, and e) and anti-BDCA-2 (d, inset) and FITC-conjugated 
secondary antibodies for anti–DC-SIGN (b and f), anti-CD1a (c), anti-CD123 
(d), anti-ChemR23 (d, inset), and antimannose receptor (MMR; f, inset). 
Magnification, 100 (a and d), 200 (e and f), and 400 (b, c, and d and f, insets). 
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HEV cells (e.g., CCL19, CXCL12, and CCL2; references 22,
23). In vitro experiments performed with five different types
of endothelial cells of different origin (i.e., cord blood, dermis,
iliac artery, and bone marrow) did not show any production
of chemerin by endothelial cells both under basal conditions
and after cytokine stimulation (TNF, IL-1, LPS, IFN
 
 
 
, IFN
 
 
 
,
and combinations of these agonists; unpublished data). There-
fore, it is unknown at the moment whether chemerin expres-
sion is a prerogative of a specialized endothelium of an ana-
tomical compartment, such as that of HEVs, or if chemerin is
produced by stromal cells surrounding HEVs, and subse-
quently transported through the fibroblastic reticular cell net-
work to HEVs (for review see references 22, 23).
 
Expression of chemerin by dermal endothelial cell 
of blood vessels in LE
 
Nonresident DCs, including P-DC, accumulate in the skin
in many inflammatory conditions (24). Thus, the expression
of chemerin was assessed in tissue sections obtained from
normal and inflamed skin. Chemerin expression was com-
pletely absent in normal skin, including in endothelial cells
of the papillary dermis vessels (Fig. 4 c). These data suggest
that chemerin is unlikely to be responsible for skin recruit-
ment of resident DCs in steady-state conditions. In recent
years, P-DC were directly implicated in the pathogenesis of
LE (5, 8). In LE patients, the number of circulating P-DC is
reduced, and these cells are present in the skin lesions, sug-
gesting that P-DC are selectively recruited to the skin (8).
Therefore, the expression of chemerin was examined in skin
biopsies from nine cases of LE. Chemerin reactivity was ob-
served in six out of the nine cases on the endothelial cells
lining dermal vessels (Fig. 4, d–f). These endothelial cells did
not express podoplanin (Fig. 4 g), a marker of lymphatic en-
dothelium (25), indicating that they belong to blood vessels.
In addition to endothelial cells, rare chemerin
 
 
 
 cells were
also observed in the epidermis and in the dermis. In the epi-
dermis, chemerin reactivity was present in scattered Langer-
hans cells (Fig. 4 d). In the dermis, sparse chemerin
 
 
 
 cells
were admixed to lymphoid infiltrates and displayed a fusate/
dendritic morphology. These cells were found to corre-
spond to DC-SIGN
 
 
 
 dendrocytes (reference 26 and unpub-
lished data). Notably, in five out of six positive cases, P-DC
were present with variable density within the skin lesions
and double immunofluorescence staining, demonstrating
that CD123
 
 
 
 P-DC are located in close proximity of
chemerin
 
 
 
 dermal endothelial cells (Fig. 4 e, inset). This
suggests that chemerin local production can direct P-DC to
the skin in inflammatory conditions characterized by P-DC
accumulation (5).
In summary, this report shows that M-DC and P-DC
express ChemR23 in vitro and in vivo. Experiments per-
formed in vitro clearly show that chemerin represents a new
chemotactic factor for blood M-DC and most importantly
for P-DC. The in vivo distribution of chemerin, located at
the luminal side of HEVs and inflamed blood dermal vessels,
strongly suggests that chemerin is involved in the migration
of P-DC across HEVs under steady-state conditions, and in
the accumulation of P-DC observed in inflamed tissues.
 
MATERIAL AND METHODS
 
Reagents.
 
Recombinant chemerin was produced and purified as de-
scribed previously (10). Human chemokines and cytokines used were:
CXCL12, CCL19 (PeproTech), IL-1
 
 
 
 (Dompè), TNF
 
 
 
 (BASF Knoll),
IFN
 
 
 
 (Roussel Uclaf), and IFN
 
 
 
 (Roferon; Roche). RPMI 1640 was ob-
tained from GIBCO BRL. FCS was obtained from Hyclone. Cytokines
and media were endotoxin free as assessed by the Limulus amoebocyte as-
say (BioWhittaker Inc.). All reagents not otherwise specified were obtained
from Sigma-Aldrich.
Figure 4. Chemerin expression in secondary lymphoid organs, 
normal skin, and cutaneous LE lesions. Immunostaining of lymph node 
sections shows chemerin reactivity on endothelial cells and sparse periven-
ular spindle cells in the interfollicular area (a and b). Chemerin  vessels 
correspond to HEV labeled by CD123 (a, inset), CLA (b), and Factor VIII (b, inset); 
note the preferential expression of chemerin on the luminal side of HEV 
(b, arrowhead). Because CLA and CD123 also stain P-DC, these markers 
also identify P-DC surrounding HEV (a and b). Chemerin is absent in nor-
mal skin (c). Chemerin  cells are numerous in the dermis from a LE case (d). 
Most of these cells correspond to endothelial cells; in addition, scattered 
chemerin  cells with fusate morphology are admixed to the lymphoid in-
filtrate (d and e). Rare chemerin  cells are also noticeable in the epidermis 
(d). Double immunofluorescence demonstrated that, in LE lesions, CD123  
P-DC (e, inset, asterisk) are located around chemerin  dermal vessels (e, inset; 
white arrowheads indicate the luminal side). On serial sections obtained 
from a LE case, chemerin  endothelial cells (f) did not coexpress the lym-
phatic endothelial cell marker podoplanin (g). Indirect immunoperoxidase 
technique was applied (a and c–g); nuclei were counterstained with hema-
toxylin. Double immunofluorescence was performed (a, inset; b; and e, in-
set) using Texas red–conjugated secondary antibodies for antichemerin 
(a and b, insets), anti-CLA (b), anti-CD123 (e, inset) and FITC-conjugated 
secondary antibodies for anti-CD123 (a, inset), antichemerin (b and e, inset), 
and anti–Factor VIII (b, inset). Magnification, 200 (b–d, f, g, and a and b, 
insets); 400 (a); and 600 (e and its inset). 
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Peripheral blood DC purification. PBMCs were isolated from buffy
coats by Ficoll gradient (Amersham Biosciences) and peripheral blood
M-DC and P-DC were magnetically sorted with blood DC Ag (BDCA)-1
and BDCA-4 cell isolation kits (Miltenyi Biotec), respectively, as described
previously (9). Blood M-DC and P-DC (106 cells/ml) were cultured in me-
dium containing 1,000 U/ml recombinant human GM-CSF (Mielogen;
Schering-Plough) and 10 ng/ml IL-13 (a gift from A. Minty, Sanofi Elf Bio
Recherches, Labège, France) or 20 ng/ml IL-3 (ProSpec), respectively.
Cells were matured by 24-h incubation with 100 ng/ml LPS (Escherichia coli
055:B5; Sigma-Aldrich), or 20 ng of hemagglutinin/ml inactivated influ-
enza virus strain A/Moscow/10/99 (a gift from T. De Magistris, Istituto
Superiore di Sanità, Rome, Italy). BDCA-3  MDC were isolated with
BDCA-3 cell isolation kit (Miltenyi Biotec), cultured in medium contain-
ing 1,000 U/ml rhGM-CSF, 10 ng/ml IL-13, and 20 ng/ml IL-3 and ma-
tured by 24-h incubation with 100 ng/ml LPS and 20 ng of hemagglutinin/
ml inactivated influenza virus (3).
Flow cytometry. The expression of ChemR23 was analyzed by FACS us-
ing two monoclonal antibodies (clone 4C7 and 1H2) described previously
(10). The expression of ChemR23 on PBMC subsets was analyzed by FACS
using: allophycocyanin-conjugated anti-CD3, PE-conjugated anti-CD20,
and PE-conjugated anti-HLA-DR (Becton Dickinson); and allophycocyanin-
conjugated anti-CD14 and PE-conjugated anti-CD16 (Exalpha). PE-conju-
gated CD123 (IgG1; clone 9F5) and CD11c (IgG2b; clone S-HCL-3) were
obtained from Becton Dickinson. Analysis of fluorescence was performed on
a FACStar Plus calibrated with Calibrite beads (Becton Dickinson).
Transendothelial migration assay. Transendothelial migration assay was
evaluated using 24-well Costar Transwell chambers (5  m pore size; Corn-
ing). Human umbilical vein endothelial cells (HUVECs; passage  5) were
subcultured to confluent monolayers on Transwell inserts and precoated with
gelatin. Monolayers were rinsed with chemotaxis medium (RPMI 1640 con-
taining 10% FCS) before use. 100  l of DC suspension (1–2   106 cells/ml)
were seeded in the upper chamber and 600  l of chemoattractant or control
medium was added to the lower well. The chamber was incubated at 37 C
in humidified atmosphere in the presence of 5% CO2 for 4 h. Migrated cells
were recovered from the lower well and counted and the results were ex-
pressed as the percentage of input cells. In some experiments, DC subsets
were cultured for 24 h in the presence or absence of a maturative stimulus
(LPS or influenza virus) and tested for their ability to migrate in response to
chemoattractants. PBMCs (10   106 cells/ml; 100  l of cell suspension per
well) migration was tested in the same experimental conditions used for DCs.
Migrated cells were collected and labeled for FACS analysis.
Chemerin expression in endothelial cells. Chemerin expression was
evaluated by RT-PCR. Total RNA samples (1  g) were reverse transcripted
using the SuperScript II Rnase H  Reverse Transcriptase (Invitrogen). PCR
was performed on cDNA samples using the following primers: chemerin for-
ward, 5 -ATGCGACGGCTGCTGATCCCTC-3 , chemerin reverse, 5 -
TTAGCTGCGGGGCAGGGCCTTG-3 ; CXCL10 forward, 5 -GGAAC-
CTCCAGTCTCAGCACC-3 , CXCL10 reverse, 5 -CAGCCTCTGT-
GTGGTCCATCC-3 ; CXCL8 forward, 5 -CGATGTCAGTGCATAAA-
GACA-3 , CXCL8 reverse, 5 -TGAATTCTCAGCCCTCTTCAAAA-3 ;
and   -actin forward, 5 -GAAGAGCTACGAGCTGCCTGA-3 ,   -actin
reverse, 5 -TGATCTTCATTCTGCTGGGTG-3 . Chemerin PCR condi-
tions were as follows: 95 C for 3 min, 95 C for 1 min, 60 C for 1 min, 72 C
for 2 min (40 cycles), and 72 C for 5 min. CXCL10/IP-10 PCR conditions
were as follows: 95 C for 5 min, 95 C for 30 s, 64 C for 1 min, 72 C for 30 s
(22 cycles), and 72 C for 15 min. CXCL8/IL-8 PCR conditions were as
follows: 95 C for 5 min, 95 C for 30 s, 58 C for 30 s, 72 C for 30 s (25 cy-
cles), and 72 C for 15 min.  -actin PCR conditions were as follows: 95 C
for 4 min, 95 C for 1 min, 50 C for 30 s, 72 C for 1 min (20 cycles), and
72 C for 10 min. Amplified products were subjected to electrophoresis on
2% agarose gels and stained with ethidium bromide. The identity of the
chemerin transcript was confirmed by sequencing. HUVECs were cultured
as specified before; human iliac artery ECs (27, 28) were grown in E199 with
10% FCS, 10% human serum; human dermal microvascular ECs were ob-
tained from PromoCell GmbH and cultured following the manufacturer’s
instructions; immortalized human dermal microvascular ECs (29) were
grown in E199 with 10% FCS, 10% human serum; human bone marrow mi-
crovascular ECs (30) were grown in E199 as HUVECs.
Tissues and reagents. Surgical specimens from human tissues including
normal skin (obtained from abdominal plastic surgery), skin biopsies from
nine cases of LE, reactive tonsils, and lymph nodes (removed for diagnostic
purposes) were analyzed. Each specimen was snap frozen in isopentane pre-
cooled to liquid nitrogen temperature and stored at  80 C. Thin cryostat
sections were air dried overnight at room temperature and fixed in acetone
for 10 min before staining. Tissue expression of ChemR23 was evaluated
by immunohistochemistry using two anti-ChemR23 monoclonal antibod-
ies, namely 4C7 (IgG2b; dilution 1:15) and 1H2 (IgG2a; 1:15; reference
10). The indirect streptavidin–biotin complex immunoperoxidase tech-
nique was applied using a biotinylated anti-Ig multilinks secondary antibody
(1:20 dilution in Tris-HCl buffer, pH 7.4; Biogenex). The 4C7 and 1H2
moAbs properly reacted on frozen sections; no signal was observed in for-
malin-fixed tissue sections. Tissue expression of chemerin was detected us-
ing two mouse monoclonal antibodies (clones 227C and 14G10; both
IgG1; dilution 1:30; 2-h incubation), directed against the peptide Cys-
QRAGEDPHSFYFPGQFAFS, a common peptide for both active chemerin
and prochemerin.
Double immunofluorescence stainings were performed using a set of
primary antibodies, including CD123 (clone 7G3; mouse IgG2a; dilution
1:40; BD Biosciences), DC-SIGN (mouse IgG2b; dilution 1:5; BD Bio-
sciences), CLA (clone Heca452; rat IgM; dilution 1:100; BD Biosciences),
CD1a (010, IgG1, dilution 1:30; Immunotech), Langerin (provided by
G. Trinchieri, Schering-Plough, Dardilly, France), and mannose receptor
(clone 3.29B1; mouse IgG1; dilution 1:50). Appropriate Texas red– and
FITC-conjugated isotype-specific secondary antibodies were used to reveal
the primary antibodies and sections were examined with a fluorescence mi-
croscope Olympus BX60, equipped with a Nikon digital camera. Anti–
human podoplanin Ab (clone 18H5, dilution 1:30; Abcam) recognizes lym-
phatic endothelium and was tested on frozen samples of breast carcinoma.
This work was conducted in accordance with a protocol approved by the
Spedali Civili of Brescia Institutional Ethical Board and informed consent
was obtained from all patients.
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